Product Details
Product Details
Product Specification
| Host | Rat |
| Antigen | IL-13 |
| Synonyms | Interleukin-13; NC30; IL13 |
| Location | Secreted |
| Accession | P35225 |
| Clone Number | S-4442 |
| Antibody Type | Rat mAb |
| Isotype | IgG1 |
| Application | ICFCM |
| Reactivity | Hu |
| Purification | Protein G |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| ICFCM | 1:200 | Hu |
Background
Interleukin-13 (IL-13) is a pleiotropic cytokine primarily secreted by activated type 2 helper T cells (Th2), group 2 innate lymphoid cells (ILC2s), mast cells, and basophils, playing a central role in regulating inflammatory and immune responses, particularly those associated with allergic reactions and parasitic infections. Structurally homologous to IL-4, IL-13 exerts its biological effects by binding to a heterodimeric receptor complex composed of the IL-4Rα chain and the specific IL-13Rα1 chain, which subsequently activates the JAK-STAT signaling pathway, notably STAT6, to modulate gene expression in target cells such as epithelial cells, fibroblasts, and B cells. Its key physiological functions include inducing class switching to IgE in B cells, stimulating mucus hypersecretion and goblet cell metaplasia in airway epithelium, promoting alternative activation (M2 polarization) of macrophages, and driving tissue fibrosis by enhancing collagen production, making it a critical mediator in the pathogenesis of asthma, atopic dermatitis, and other fibrotic disorders, thereby establishing it as a major therapeutic target for biologics like dupilumab and tralokinumab that aim to block the IL-4/IL-13 signaling axis.
